Discover the 2023 Cell Therapy Landscape Review
A comprehensive analysis of the drug, trial, and commercial landscape, including updates from 2023, relevant regulatory announcements, and the future of the cell therapy landscape.
About the 2023 Landscape Review
The Cell Therapy field is evolving fast. CAR T cells and CD19 are the most commonly developed therapeutic classes. Armored cell therapies with KI, KO, and KD genes are gaining interest. In 2023, cell therapy expanded, particularly in autoimmune diseases. Exagamglogene autotemcel, the first CRISPR-edited cell therapy received landmark approval.
Developers are moving away from developing T Cells and into NK cells. Over 60% of NK therapies are allogeneic versus only 21% of T cell therapies. It’s important to follow trends in patient enrolment for early phase trials for non-oncology indications, with a 10% growth rate in non-oncology deals compared to a 10% decrease in cancer indications. Get all this information and more in our 2023 Cell Therapy Landscape report. Download now.
You may also be interested in...
H1 2024 Immune Tolerance Landscape Review
H1 2024 RNA Landscape Review
H1 2024 Gene Therapy Landscape Review
H1 2024 Cell Therapy Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Webinar – Exploring Allogeneic Cell Therapies: Pioneering Advantages and Recent Innovations
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.
With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Any questions? Get in touch
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
